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Abstract
Accumulation of b-Amyloid (bA) is a key pathogenetic factor in Alzheimer’s disease; however, the normal function of bAi s
unknown. Recent studies have shown that bA can inhibit growth of bacteria and fungi. In this paper we show that bA also
inhibits replication of seasonal and pandemic strains of H3N2 and H1N1 influenza A virus (IAV) in vitro. The 42 amino acid
fragment of bA( bA42) had greater activity than the 40 amino acid fragment. Direct incubation of the virus with bA42 was
needed to achieve optimal inhibition. Using quantitative PCR assays bA42 was shown to reduce viral uptake by epithelial
cells after 45 minutes and to reduce supernatant virus at 24 hours post infection. bA42 caused aggregation of IAV particles
as detected by light transmission assays and electron and confocal microscopy. bA42 did not stimulate neutrophil H2O2
production or extracellular trap formation on its own, but it increased both responses stimulated by IAV. In addition, bA42
increased uptake of IAV by neutrophils. bA42 reduced viral protein synthesis in monocytes and reduced IAV-induced
interleukin-6 production by these cells. Hence, we demonstrate for the first time that bA has antiviral activity and modulates
viral interactions with phagocytes.
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Introduction
bA accumulation is believed to contribute strongly to the
pathogenesis of Alzheimer’s disease, although the actual physio-
logical function and reason for accumulation of bA in the brain are
not known. bA is a fragment of the larger b amyloid precursor
protein (APP) which is a transmembrane protein which can be
broken down by various proteases into a variety of fragments,
including extracellular and intracellular fragments and the
fragments bA42 and bA40 which are composed partly of the
extracellular and partly of the transmembrane domain of APP.
bA40 is more abundant than bA42, but bA42 is the more
amyloidogenic species [1–3]. bA has been shown to induce
neurotoxicity and clinical trials have been focused on reducing its
concentration to treat Alzheimer’s disease. The structure of bA
resembles that of antimicrobial peptides like protegrin and, like
protegrin, it can form membrane channels [4]. Importantly, recent
studies have demonstrated antibacterial and antifungal activity of
bA peptides [5,6]. There is evidence that these antibacterial and
antifungal activities are mediated by the ability of bA peptides to
form membrane pores. This implies that bA may play a role in
innate defense against infection.
bA accumulation in the brain has been demonstrated in HIV
related dementia and recent findings suggest that this results from
HIV-induced impairment in proteolysis of bA [7]. Herpes Simplex
Virus (HSV) induced encephalitis is associated with bA accumu-
lation in affected areas of the brain, and HSV infection of cell
cultures in vitro results in bA accumulation [8]. Of interest,
treatment with antivirals reduced accumulation of bA in HSV-
infected cell cultures. These findings suggest that viruses that infect
the brain could be triggers for accumulation of bA. The triggers of
bA production and a full understanding of which cells produce bA
in vivo are not clear. bA was detected in plasma, cerebrospinal
fluid and culture medium of mixed brain cell cultures in an early
study [9]. If bA does function as an innate defense protein one
might expect it to be produced during infectious or inflammatory
states (as suggested by the HSV findings).
Antimicrobial peptides also frequently function as ‘‘alarmins’’,
triggering recruitment and activation of immune cells [10]. bA
peptides are also pro-inflammatory, triggering activation of glial
cells and macrophages, and this is thought to relate to neuronal
injury [11]. Activation of glial cells by bA has been found to be
mediated by TLR2 [12]. These phagocytic cells may also play a
role in clearance of bA peptides through phagocytosis and
enzymatic degradation of the protein.
In this paper we use influenza A virus (IAV) as a model system
to test for antiviral effects of bA peptides. We also study how the
peptides alter interactions of IAV with neutrophils and monocytes.
PLOS ONE | www.plosone.org 1 July 2014 | Volume 9 | Issue 7 | e101364We demonstrate that bA peptides have antiviral and immuno-
modulatory effects similar to other anti-microbial peptides (e.g.
defensins). These studies should open the way for more studies of
the effects of bA peptides on other viruses and phagocytes.
Materials and Methods
Ethics statement
Blood collection for isolation of neutrophils and monocytes was
done with informed consent as approved by the Institutional
Review Board of Boston University School of Medicine. The
Institutional Review Board specifically approved this study and
also approved the consent form for the study. The blood donors
were healthy volunteers and they all signed the written consent
form prior to each donation.
Virus Preparations
Philippines 82/H3N2 (Phil82) strain was kindly provided by Dr.
E. Margot Anders (Univ. of Melbourne, Melbourne, Australia)
and grown in the chorioallantoic fluid of ten day old chicken eggs
and purified on a discontinuous sucrose gradient as previously
described [13]. Aichi68 H3N2 was obtained from ATCC and PR-
8 was kindly provided by Jon Abramson (Wake Forest University)
these strains were prepared in eggs in a similar manner. The
viruses were dialyzed against PBS to remove sucrose, aliquoted
and stored at 280uC until needed. Post thawing the viral stocks
contained ,5610
8 infectious focus forming units/ml. The A/
California/2009 H1N1 pandemic strain (Cal09) and the A/New
York/2001 H1N1 (NY01) seasonal strain were prepared by
reverse genetics as described [14].
bA Preparations
bA42 and bA40 were obtained from AnaSpec, Fremont, CA.
bA42 prepared through an alternative method (Hexafluoro-2-
propanol, HFIP) was purchased from Phoenix Pharmaceuticals,
Burlingame, CA, USA. LL-37 was obtained from Abigent Inc.
WRW4 peptide was obtained from Phoenix Pharmaceuticals,
Burlingame, CA.
Hemagglutination (HA) inhibition assay
HA inhibition was measured by serially diluting bA in round
bottom 96 well plates (Serocluster U-Vinyl plates; Costar,
Cambridge, MA) using phosphate buffered saline (PBS) as a
diluent and human type O red cells as described.
Fluorescent focus assay of IAV infectivity
MDCK cell monolayers were prepared in 96 well plates and
grown to confluency. These layers were then infected with diluted
IAV preparations for 45 min. at 37uC in PBS. MDCK cells were
tested for presence of IAV infected cells after 7 hrs of virus
addition using a monoclonal antibody directed against the
influenza A viral nucleoprotein (provided by Dr. Nancy Cox,
CDC, Atlanta, GA) as previously described. IAV was pre-
incubated for 30 min. at 37uC with various concentrations of bA
or control buffer, followed by addition of these viral samples to the
MDCK cells. In some assays, human bronchial tracheal epithelial
cells (HBTE) cells or small airway epithelial cells were used. These
cells were purchased from the American Type Culture Collection
(Manassas, VA) and propagated in the undifferentiated state in
standard tissue culture flasks. For neutralization experiments the
multiplicity of infection (MOI or ratio of virus particles to
epithelial cells) was 0.1.
Lactate dehydrogenase (LDH) assay
The LDH assay was performed on MDCK cells infected with
Phil82 IAV and bA42 or treated with bA42 alone. Controls
included uninfected cells and cells infected with IAV without any
peptide added. The assay was performed according to the
manufacturer’s instructions (Clontech, CA). In brief the assay
includes positive and negative controls and is an ELISA. The
percent cytotoxicity is obtained from OD values by the formula:
OD490positive control 2 OD490negative control 4 OD490positive control
6Sample OD490.
Measurement of viral RNA
RNA for the viral M protein was measured using a quantitative
real time PCR as previously described [15]. MDCK cells were
infected with IAV virus strains incubated for 30 min at 37uC with
or without various doses of bA42. RNA extraction was done at
45 min and 24 hrs post infection using Magmax viral RNA
isolation kit (Applied Biosytems, Carlsbad, California) as per
manufacturer’s instructions. For these experiments we used and
MOI of 1 since the concentration used on the neutralization assays
were too low to register reliably by the PCR assay after 45 min of
infection. Both lysed cells and cell supernatant were used for
extraction. Viral RNA was also extracted from different concen-
trations of virus with known FFC/ml which was used as standard
series. RNA was reverse transcribed using TaqMan reverse
transcription reagents (Applied Biosytems, Carlsbad, California).
The reaction mix and the cycle conditions were as per
manufacturer’s instructions. For real time PCR, primers specific
for IAV M protein (Forward AGA CCA ATC CTG TCA CCT
CTGA and Reverse: CTG CAG TCC TCG CTC ACT) were
used. The primers and TaqMan-labeled probes with non-
fluorescent minor groove binder (MGB) moieties were designed
manually using the Primer Express software version 3.0 (Applied
Biosystems, Carlsbad, California) and were also synthesized by
Applied Biosystems. The assay sequences were examined for
specificity by nucleotide BLAST. The experiment was performed
in a 7500 Real time PCR system (Applied Biosytems, Carlsbad,
California) using volume of 20 mL containing 2 ul of template
cDNA, 0.9 uM primer 0.25 uM of 6-FAM dye-labeled TaqMan
MGB probe (6-FAM-ATT TGT GTT CAC GCT CAC CGT G-
MGB), and 16 TaqMan Universal PCR master mix (Applied
Biosytems, Carlsbad, California). Thermal cycling proceeded at
50uC for 2 min, 95uC for 10 min followed by 40 cycles of 95uC for
15 s, 60uC for 1 min and 72uC for 30 s. For calculation of FFC/
ml from the Cycle threshold (Ct) values, we first plotted a standard
curve using the known Log10 values of FFC/ml and corresponding
Ct values. The Ct values of samples were converted to log 10
values of FFC/ml (x) using the formula y=mx+c where y is the Ct
value, m is the slope and c is the intercept. Slope and intercept
were calculated from the standard curve using Micosoft Excel.
Log10 values of FFC/ml were converted to FFC/ml by doing an
anti-log (10‘log10 value).
Measurement of viral aggregation by bA and electron
microscopy
Viral aggregation caused by bA was measured by assessing light
absorbance at 350 nM by suspensions of IAV. This was done
using a Perkin Elmer Lambda 35 UV/Vis spectrophotometer. In
addition, viral aggregation was assessed using electron microscopy
(EM) as described [16]. In brief, bA42 was incubated with Aichi68
IAV at 37uC for 30 minutes, and a 4 ml sample was placed on each
copper grid. After the unbound virus was blotted off, the grid was
fixed with 4 ml of 2.5% glutaraldehyde for 5 minutes. Samples
Antiviral and Immuno-Modulatory Activities of b-Amyloid
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Aldrich, St. Louis, MO) for 10 seconds, and excess stain was
blotted off. The grids were then air dried and stored in a grid box
until examined with a Phillips 300 electron microscope (Mahwah,
NJ).
Confocal microscopy
For these experiments the Aichi68 IAV was labeled with Alexa
Fluor 594. Alexa Fluor 594 carboxylic acid, succinimidyl ester
labeling kit was purchased from Molecular Probes and labeling
was carried out using manufacturer’s recommendations with some
modifications. In brief, concentrated virus stock was incubated
with the Alexa Fluor in sodium bicarbonate buffer (pH 8.3) for
one hour at room temperature. The preparation was then dialyzed
overnight against PBS at 4uC. After this procedure there was no
reduction in viral hemagglutination titer. MDCK cells were pre-
incubated with the labeled virus for 45 min., followed by washing
and fixation using 1% paraformaldehyde. Prior to this the IAV
was either pre-incubated with control buffer or bA for 30 minutes
at 37uC in the same manner as in the infectious focus assay. Wheat
germ agglutinin (WGA)-Oregon Green 488 (4 mg/ml) and DAPI
350 were used to stain the cell membrane and nucleus respectively.
Confocal pictures were taken at Zeiss LSM510 (LSEB) on 1006
resolution.
Human Neutrophil and Monocyte Preparation
Neutrophils from healthy volunteers were isolated to .95%
purity by using dextran precipitation, followed by Ficoll-Paque
gradient separation for the separation of mononuclear cells
(layering above the Ficoll-Paque) and neutrophils (below the
Ficoll-Paque). The neutrophils were purified further by hypotonic
lysis to eliminate any contaminating erythrocytes, as previously
described. Cell viability was determined to be .98% by trypan
blue staining. The isolated neutrophils were resuspended at the
appropriate concentrations in control buffer (PBS) and used within
2 hours. Peripheral blood mononuclear cells (PBMCs) were taken
from the layer above Ficoll-Paque and washed several times in
PBS. Monocytes were isolated from the PBMC preparations by
negative selection using magnetic beads using a Miltenyi monocyte
isolation kit (catalogue number 130-091-153).
Measurement of IAV uptake by neutrophils and
monocytes
Fluorescein isothiocyanate (FITC)-labeled IAV (Phil82 strain)
was prepared and uptake of virus by neutrophils or monocytes was
measured by flow cytometry as described [17]. In brief, IAV was
treated with various doses of bA peptides for 30 min at 37uC.
Then it was incubated with cells for 45 minutes at 37uCi n
presence of control buffer. Trypan blue (0.2 mg/ml) was added to
these samples to quench extracellular fluorescence. Following
washing, the neutrophils were fixed with 1% paraformaldehyde
and neutrophil and monocyte associated fluorescence was
measured using flow cytometry. The mean cell fluorescence (.
2000 cells counted per sample) was measured. For the experiments
involving neutrophils and monocytes (e.g. viral uptake, NET
formation, H2O2 production and cytokine generation the MOI
was ,40).
Assessment of neutrophil extracellular trap (NET)
formation
For NETs study, neutrophils were resuspended in PBS
supplemented with Ca
2+ and Mg
2+ and allowed to adhere on
Poly-L-Lysine coated 96 well plates or on glass bottom culture
dishes (MatTek corporation, Ashland, MA) for 1 hr in a CO2
incubator. After 1 hr, unadhered cells were removed and adhered
cells were incubated for 3 hrs in a CO2 incubator with Phil82 virus
after preincubation of the virus (30 min, 37uC) with bA42. For
quantitative assessment of NETs formation, Sytox green (Life
Technologies) was added to samples on 96 wells plate after the
3 hr incubation period and the plate was read on POLARstar
OPTIMA fluorescent plate reader (BMG Labtech, Durham NC).
Immediately after reading the plate, the plate was also photo-
graphed on a fluorescent microscope as well.
Assay of tumor necrosis factor alpha (TNFa) and IL-6
production by human monocytes
Human peripheral blood monocytes were isolated by magnetic
bead separation as described above and infected with an MOI of
,50 of Phil82 IAV for 45 min at 37uC. The virus was either used
alone or after 45 min incubation with various concentrations of
bA. After this the cells were pelleted, washed with PBS and then
Figure 1. Viral neutralizing activity of bA42 and 40 for seasonal H3N2 and pandemic H1N1 strains of IAV. Aliquots of the Phil82 H3N2
(panel A) or Cal09 H1N1 (panel B) viral strains were incubated with the indicated concentrations of bA42 or 40 or a scrambled version of bA42 and
then these samples were used to infect HBTE cell monolayers and tested for infectious foci 7 hrs later using anti-nucleoprotein antibodies and
fluorescence detection. * indicates significant reduction in infectivity compared to control (p,0.05; n=4 experiments) ** indicates p,0.02 compared
with bA40, scrambled bA42 and control (ANOVA analysis) # indicates increased infectivity compared to control.
doi:10.1371/journal.pone.0101364.g001
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in a CO2 incubator. After 18 hrs, supernatant was collected and
assayed for TNFa using a sandwich ELISA method (catalog
number MTNFAI; Endogen), following the manufacturer’s
instructions. The IL-6 ELISA was performed using a kit from
Abcam (Cambridge, MA, USA).
Measurement of neutrophil H2O2 production
H2O2 production was measured by assessing reduction in
scopoletin fluorescence as previously described. Measurements
were made using a POLARstar OPTIMA fluorescent plate reader
(BMG Labtech, Durham NC).
Statistics
Statistical comparisons were made using Student’s paired, two-
tailed t test or ANOVA with post hoc test (Tukey’s). ANOVA was
used for multiple comparisons to a single control.
Results
Neutralization of IAV strains by bA preparations
As shown in figure 1A, bA42 and bA40 peptides significantly
inhibited infectivity of a seasonal H3N2 strain of IAV (Phil82) to
infect HTBE cells. For neutralization experiments we used an
MOI of 0.1 to enable counting of infected cells. A scrambled
version of bA42 did not have any activity in this assay. bA42 had
significantly greater anti-viral activity than bA40. As shown in
figure 1 panel B, bA40 and 42 also inhibited an H1N1 pandemic
strain from 2009 (Cal09). Again the effect of bA42 was
significantly greater than that of bA40. BA42 also reduced
infectivity of IAV for small airway epithelial cells (e.g., 16 mg/ml
of BA42 reduced infectivity of Phil82 to 29612% of control and
Cal09 to 47615% of control; n=6; p,0.01 compared with viral
control in both cases; data not shown).
We used MDCK cells to make additional comparisons of the
effects of BA42 on infectivity of several different H3N2 and H1N1
Figure 2. Viral neutralizing activity of bA42 preparations for various IAV strains. Experiments were carried out as in figure 1 except that
MDCK cells were used instead of HTBE cells. Panel A shows inhibition of two H3N2 strains as indicated. Panel B shows inhibition of three H1N1 strains.
Panel C shows effects of a different commercially available preparation of bA42 (called bA42 HFIP) against Phil82 and Cal09 strains. Panel D shows the
effect of bA42 on infection of A549 cells by Aichi68 IAV and compares the effects of pre-incubating the virus with bA42 as in panel A (‘‘pre-incubate
with IAV’’) with pre-incubating the cells with bA42. In the latter case, the bA42 was either left in the cell media when virus was added (‘‘no wash’’) or
washed off prior to adding the virus (‘‘wash’’). Although in the ‘‘no wash’’ setting infectivity was significantly reduced this effect was significantly less
than when the virus was pre-incubated with bA42 (p,0.01). Finally panel D also shows the effect of pre-incubating cells with IAV at 4uC to allow
binding, followed by adding bA42, and increasing the temperature to 37uC (‘‘bA42 at 4uC’’). * indicates significant reduction in viral infectivity
compared with control (virus alone) (p,0.01). ** indicates where the Aichi68 strain was inhibited significantly more than the Phil82 strain (panel A).
Results shown are mean6SEM of 4 or more experiments.
doi:10.1371/journal.pone.0101364.g002
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greater neutralizing activity against the Aichi68 pandemic H3N2
strain than against the seasonal Phil82 H3N2 strain (figure 2A).
The activity of bA42 against Cal09 was equal to or greater than its
activity against the seasonal NY01 H1N1 strain or the mouse
adapted PR-8 H1N1 strain. Note, however, that the antiviral
activity of bA42 for Cal09 was somewhat less in MDCK cells
(figure 2C) than in HTBE cells (figure 1). We also tested the
activity of an additional preparation of bA42 against Phil82 and
Cal09 strains. This bA42 protein was prepared using HFIP to
avoid protein self-aggregation during purification. As shown in
figure 2C, the bA42 HFIP preparation inhibited both IAV strains.
The antiviral effect of bA42 was also seen with A549 cells as
shown with the Aichi68 H3N2 virus (figure 2D; ‘‘Virus+bA42’’).
In all experiments described thus far the viruses were pre-
incubated with bA42 prior to adding the mixture to cells. In
figure 2D we also tested the effects of adding bA42 to cells prior to
adding the virus. The bA42 was either left in the medium when
virus was added (‘‘no wash’’) or washed off prior to adding the
virus (‘‘wash’’). As shown in figure 2D, washing off the bA42
completely eliminated the antiviral effect, while leaving bA42 in
the medium resulted in a partial inhibition much reduced as
compared to the experiments in which virus and bA42 were pre-
incubated together. This suggests that the antiviral effect of bA42
is largely mediated by its direct interaction with the virus. We also
tested incubation of the cells with virus for 45 at 4uC followed by
adding bA42 and then raising the temperature to 37uC (‘‘BA42 at
4uC’’). Using this method no evident inhibition of infection was
observed. This suggested also that the interaction of bA42 with
free virus (prior to viral binding to cells) was critical.
To be sure that the observed antiviral activity of bA42 was not
an artifact of cell injury caused by the peptide we performed LDH
assays on MDCK cells treated with bA42 alone (at 20 and 40 mg/
ml) or bA42 at the same concentrations in the presence of Phil82
IAV. The conditions for these experiments were the same as for
the infectious focus assays. The assay uses a positive and negative
control to determine the % of cellular cytotoxicity. bA42 alone or
in presence of virus did not increase cytotoxicity significantly over
untreated MDCK cells and all treated cells were #1% cytotoxicity
(data not shown; 4 separate experiments done).
To further probe the mechanism of antiviral activity of bA42 we
performed quantitative PCR assays for the viral M protein to
determine if the peptide reduced viral uptake by epithelial cells at
45 min after infection. For these experiments we used and MOI of
1 since the concentration used on the neutralization assays were
too low to register reliably by the PCR assay after 45 min of
infection. As shown in figure 3A, bA42 did significantly reduce the
amount of viral RNA taken up into the MDCK cells while
increasing the amount of virus remaining in the supernatant. This
finding indicates that the mechanism of antiviral activity of bA42
involves at least in part reduced uptake by epithelial cells. We also
tested whether viral RNA present in cells and cell supernatants was
reduced by bA42 at 20 hrs after infection. Figure 3B shows a
strong reduction in cellular or supernatant viral RNA at this time
in samples where the virus was pre-treated by bA42.
We have previously reported that HNPs, retrocyclins and LL-37
do not inhibit viral hemagglutination activity, despite the fact that
all these peptides cause viral neutralization. Similarly bA peptides
did not inhibit HA activity of the Phil82 strain (data not shown).
Viral aggregation in response to bA peptides
Some other innate viral inhibitors like human neutrophil
defensins (HNPs), collectins and ficolins induce viral aggregation.
As shown in figure 4, bA42 caused significant dose related
aggregation of H3N2 IAV (Aichi68 strain) as assessed by light
transmission assay. Figure 5 demonstrates the aggregates formed
by bA42 using confocal microscopy. In the control panel the virus
(red color) is barely visible. In the bA42 treated samples definite
visible aggregates are present. The aggregates were also demon-
strated using electron microscopy (bottom panels figure 5).
Figure 3. Effects of bA42 on viral internalization and viral
replication in MDCK cells as determined by quantitative RT-
PCR. In panels A, Phil82 IAV was pre-incubated with the indicated
concentrations of bA42, followed by incubation of these samples for
45 min with MDCK cells as in figure 1. The cell supernatant and cell
pellets were then harvested and viral RNA was extracted followed by
PCR assay to determine the amount of virus present in cells and
supernatant. bA42 significantly reduced the amount of virus taken up
by cells after 45 min of infection. There was a trend to increased virus in
the supernatant after 45 min of infection but this was not significant.
Panel B shows the results of cell and supernatant assays after 24 hrs of
infection. bA42 significantly reduced the amount of virus in both cell
and supernatant at this time. * indicates p,0.05 compared with control.
Results are mean6SEM of three experiments.
doi:10.1371/journal.pone.0101364.g003
Figure 4. Viral aggregation induced by bA42. Aggregation of the
Aichi68 H3N2 viral strain was assessed based on increased light
absorbance at 350 nM through a stirred viral suspension. Aggregation
was significant (n=5; p,0.02) at the 16 mg/ml concentration of bA42 as
compared to light transmission through the control virus preparation.
doi:10.1371/journal.pone.0101364.g004
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For neutrophil and monocyte experiments we used considerably
higher concentrations of IAV (i.e. MOI of ,40) at which the virus
acts as an agonist for phagocytes as previously described [18]. Our
goal was to determine if bA peptides modulate this agonist activity.
IAV alone triggers a respiratory burst response in human
neutrophils and this response is increased by pre-incubating IAV
with collectins. We tested the various preparations of bA alone and
these did not provoke any neutrophil H2O2 response (data not
shown). Pre-incubation of Phil82 IAV with bA42 resulted in a
significant increase in the IAV-induced response (figure 6A). bA42
HFIP caused a similar significant increase in H2O2 production
(data not shown). In contrast, scrambled bA42 (panel A) and bA40
(panel B) did not significant increase H2O2 production beyond
that induced by IAV alone. Pre-incubation of IAV with bA42
resulted in a significant increase in neutrophil uptake of IAV
(figure 7A). Pre-incubation of IAV with bA42 also increased
production of NETs in response to virus (figure 7B). bA42 has
been shown to bind to formyl peptide receptors on glial cells
leading to cellular responses [19]. In view of this we tested the
effects of the formyl peptide receptor blocker on NET formation.
This blocker, WRW4, had no effect on NET formation in
response to IAV or IAV+bA42 (figure 7B). We tested two formyl
peptide receptor agonist, fMLP and WKYVM and neither of these
induced NET formation (data not shown). Figure 8 shows
fluorescent micrographs indicating increased IAV-induced NET
formation when either Phil82 or Aichi68 strains of IAV were pre-
incubated with bA42. bA42 alone did not induce any increase in
NET response compared to buffer alone.
Effects of bA on monocyte interactions with IAV
bA42 significantly reduced the percentage of monocytes
expressing viral nucleoprotein at 18 hrs after infection
(figure 9A). Of interest, pre-incubation with bA42 resulted in
increased uptake of fluorescently labeled IAV by monocytes after a
45 min incubation (figure 9B). Phil82 IAV induced robust TNF
and IL-6 production after 18 hrs of infection as previously
reported. The mean TNF production from uninfected control,
IAV-infected cells and cells exposed to 20 mg/ml of bA42 alone
were: 662, 52614, and 462 ng/ml, respectively (p,0.001 for
IAV treated vs control; n=8). Similarly, IL-6 levels for control,
IAV infected or bA42 treated cells were: 1663, 3666, and
2064 ng/ml (p,0.01 for IAV-infected vs control; n=4). The
monocytes were treated with bA42 alone did not make
significantly more TNF or IL-6 than controls in these experiments.
Pre-incubation of the virus with bA42 did not alter IAV-induced
Figure 6. Neutrophil H2O2 responses to IAV alone or IAV treated with bA42 or bA40. Human neutrophils were treated with buffer alone
(PBS), IAV alone (Phil82) or IAV that had been pre-treated with bA42 or scrambled bA42 (panel A) or bA40 (panel B) (all at 16 mg/ml). bA42 caused a
significant increase in H2O2 response compared to IAV alone or IAV pre-treated with the scrambled peptide of bA40 (indicated by **). Note that the
latter two proteins did not increase the response compared to IAV alone. Results are mean6SEM from 5 experiments (each with a separate neutrophil
donor).
doi:10.1371/journal.pone.0101364.g006
Figure 5. Confocal and electron microscopy demonstrating
viral aggregates formed by bA42. Alexafluor 594-labeled Aichi68
IAV was incubated with control buffer or bA42 at the indicated
concentrations. After this the virus +/- bA42 samples were added to
MDCK cell monolayers as described in Methods. The virus appears red,
cell nuclei were stained with Dapi 350 and appear blue, and cell
membranes were labeled with WGA-Oregon Green 488. The upper
pictures show the same fields as those below but the middle pictures
only show the wavelength of virus. Aggregates were also observed on
electron microscopy (bottom row of pictures). Results are representa-
tive of three similar experiments. The pictures were taken at 1006
magnification.
doi:10.1371/journal.pone.0101364.g005
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(figure 9C; results expressed as % of viral control).
Discussion
We demonstrate for the first time that bA peptides have
antiviral activity. The bA peptides had antiviral activity not only in
MDCK cells but in more physiological cell models (primary
tracheobronchial or small airway cells). The antiviral activity of
bA42 appeared to be somewhat greater in the HTBE cells than in
MDCK cells. The antiviral activity of bA42 was significantly
greater than that of bA40. This is in agreement with findings of
Soscia et al that bA42 has greater anti-bacterial and anti-fungal
activity than bA40 [6]. It is notable that the peptides also inhibited
the Cal09 H1N1 pandemic strain which is not inhibited by several
other innate inhibitors including the collectins, MBL and SP-D, or
pentraxin [16,20]. Using quantitative PCR assays we show that
bA42 reduces uptake of IAV by epithelial cells which accounts at
least in part for its antiviral activity. We also show that bA42
reduces both cellular and supernatant viral RNA at 24 hours after
infection. In addition, we show that it is critical to pre-incubate the
virus with bA42 to achieve optimal inhibition. Hence, the peptide
appears to mainly act on the virus itself rather than on the cell to
achieve neutralization. In agreement with prior findings obtained
with defensins, retrocyclins and LL-37, bA peptides did not inhibit
HA activity of IAV [15,21]. Our results further suggest that the
ability of bA42 to cause viral aggregation may in part account for
viral inhibition. Specifically, pre-incubation of epithelial cells with
the virus at 4C (allowing binding of virus but not internalization),
followed by addition of bA42 caused no inhibition of infectivity.
The findings that bA42 is able to induce viral aggregation is of
interest and may reflect the self-aggregating potential of this
peptide [1]. We have proposed a similar mechanism for the ability
of HNPs and retrocyclins to induce viral aggregation [21,22]. In
contrast, LL-37 does not induce any viral aggregation and inhibits
Figure 7. bA42 increases neutrophil uptake of IAV and IAV-induced NET formation. In panel A, neutrophils were treated with FITC-labeled
Phil82 IAV alone or virus pre-incubated with the indicated peptides. bA42 and bA42 HFIP significantly increased viral uptake by the neutrophils
(indicated by * for both; n=4; p,0.03 compared with control). The amounts of bA shown are those that were initially incubated with IAV prior to a
dilution which occurred when these samples were added to the neutrophils. For example where 50 mg/ml is shown in figure 7A or 9B the final
concentration with cells was 14 mg/ml. The scrambled peptide and bA40 did not increase viral uptake. Panel B shows NET formation in response to
control buffer, IAV alone, bA42 alone or IAV pre-incubated with either 16 or 32 mg/ml of bA42. Sytox green fluorescence was measured by plate
reading fluorometer after 30 min of treatment at 37uC. The results shown are mean6SEM of 5 experiments using separate neutrophil donors. The
open bars are results of the stimuli in control cells. The black bars are results obtained with cells pre-treated with the WRW4 peptide which inhibits
responses mediated by formyl peptide receptors. * indicates p,0.01 vs control buffer. ** indicates p,0.01 vs IAV alone. The WRW4 peptide did not
reduce responses to any stimulus.
doi:10.1371/journal.pone.0101364.g007
Figure 8. Fluorescent micrographs of NET formation in
response to IAV and/or bA42. Panel A: Results are representative
of 4 experiments using different neutrophil donors. The figures to the
left show Sytox green fluorescence and those to the right in this panel
show the same fields under phase contrast microscopy to illustrate how
many neutrophils were present. These pictures were taken at 406and
enlarged to match the size of the cells in panel B. Panel B are
representative of another set of 3 experiments using Phil82 or Aichi68
viral strains as indicated phase and show Sytox green fluorescence
taken at 1006magnification.
doi:10.1371/journal.pone.0101364.g008
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mechanism of antiviral activity of bA peptides involves reduced
viral uptake by epithelial cells, possibly as a result of viral
aggregation. We cannot exclude the possibility that bA peptides
also alter viral membranes to reduce infectivity. Future studies
with more sensitive EM techniques might clarify this.
Antimicrobial peptides have many immune modulating effects
and recent studies suggest that bA peptides have similar effects.
We show that bA42 increases neutrophil uptake of IAV and also
increases neutrophil respiratory burst responses to the virus. Other
types of amyloid fibrils have been shown to induce NET formation
[23] and we now show that bA42 induces NETs but only in the
presence of virus. Since bA42 has been reported to mediate some
of its effects on glial cells through formyl peptide receptors [12]
which are also present on neutrophils [24], we tested whether a
blocker of these receptors would alter the enhanced NET
formation caused by bA42. This blocker had no effect in this
assay so it does not appear that this effect of bA42 is mediated by
formyl peptide receptors. Of interest, bA42 significantly increased
monocyte uptake of IAV after 45 min of incubation but viral
protein production was reduced at 20 hrs. This indicates that the
virus taken up in the presence of bA42 does not replicate in the
cells. Based on these findings bA42 appears to help in viral
clearance by phagocytes. bA42 reduced IAV-induced IL-6 but not
TNF production by these cells. Further studies of the immuno-
modulatory effects of bA peptides, or their interaction with other
innate immune molecules, will be of great interest [25].
bA peptides have been found at low concentration in human
serum and at high concentration in brain tissue of patients with
Alzheimer’s disease. It is not clear if local production of bA
peptides occurs during inflammation in other parts of the body.
Since IAV predominantly replicates in the respiratory tract
significant amounts of bA would need to be present in respiratory
lining fluids or lung to participate in viral inhibition. Avian strains
(e.g. H5N1) can cause direct brain infection in mice although CNS
infection during human influenza is extremely rare [26]. In
addition, neurological sequelae of IAV infection are well
documented (e.g. the encephalitis which resulted from the 1918
pandemic). It has not been determined if such sequelae are
associated with bA accumulation in the brain. In any case, our
findings may have more relevance to other viruses that infect the
CNS including HIV and HSV. HIV related dementia is associated
with accumulation of bA in the brain [7]. Strong associations of
HSV infection with bA production and accumulation have been
reported as well [27]. Cytomegalovirus infection has also been
associated with Alzheimer’s disease [28]. Further studies of
antiviral activity of bA against these viruses would be of great
interest. It would also be of great interest to determine if IAV
induces increased bA production in various cell types. Our studies
show that bA has both antiviral activity and strong immuno-
modulatory effects using IAV as a model system and extension of
these studies to other viruses, including those linked to Alzheimer’s
disease or brain infection will be of great interest.
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